Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” 

Rhea-AI Summary

Lexicon Pharmaceuticals (NASDAQ: LXRX) published a white paper titled “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” summarizing findings from an October 2025 Roundtable of patients, clinicians, advocates, and other stakeholders.

The paper highlights that chronic pain affects one in four American adults, costs the U.S. >$720 billion annually (including ~$190 billion in lost productivity), and calls for swift policy action to expand access to novel non-opioid therapies, citing the recently introduced Relief of Chronic Pain Act.

News Market Reaction

-0.85%

1 alert

-0.85% News Effect

On the day this news was published, LXRX declined 0.85%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Annual pain cost: more than $720 billion Lost productivity: $190 billion High-impact pain patients: more than 20 million people +5 more

8 metrics

Annual pain cost more than $720 billion Total annual cost of chronic pain in the United States

Lost productivity $190 billion Estimated annual lost worker productivity from chronic pain

High-impact pain patients more than 20 million people Americans with high-impact chronic pain

Americans with chronic pain more than 60 million Americans People living with chronic pain in the United States

Current share price $1.18 Pre-news price level for LXRX

52-week range $0.2836–$1.66 LXRX 52-week low and high prior to this article

Market cap $425,176,666 LXRX market capitalization before this news

200-day MA $1.04 LXRX 200-day moving average ahead of this announcement

Market Reality Check

Price: $1.37 Vol: Volume 1,201,821 vs 20-da...

normal vol

$1.37 Last Close

Volume Volume 1,201,821 vs 20-day average 1,627,726, indicating relatively muted trading activity. normal

Technical Shares at $1.18 are trading above the 200-day MA of $1.04 ahead of this policy-focused update.

Peers on Argus

LXRX showed a modest 0.85% gain while peers were mixed: FULC up 1.3%, AURA down ...

LXRX showed a modest 0.85% gain while peers were mixed: FULC up 1.3%, AURA down 3.37%, SLDB down 5.18%, ATXS down 1.37%, and INBX essentially flat at 0.01%, suggesting stock-specific dynamics rather than a sector-wide move.

Historical Context

5 past events · Latest: Jan 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 07	Conference presentation	Positive	+2.6%	Announcement of J.P. Morgan Healthcare Conference presentation and webcast availability.
Dec 10	Preclinical data	Positive	+0.8%	Preclinical ACSL5 data reinforcing rationale for LX9851 and Novo Nordisk license.
Dec 05	Clinical data forum	Positive	-1.4%	Upcoming presentation of sotagliflozin adipose distribution data in HFpEF patients.
Nov 25	Investor conferences	Neutral	-0.7%	Participation in two December 2025 investor conferences with webcast access.
Nov 11	Investor conference	Neutral	+9.9%	Jefferies London Healthcare Conference fireside chat announcement and webcast link.

Pattern Detected

Recent LXRX news, largely conferences and scientific updates, has produced mixed price reactions, with both gains and declines following generally neutral-to-positive announcements.

Recent Company History

Over the last few months, Lexicon’s news flow has centered on conferences, preclinical publications, and investor outreach. Events include multiple healthcare conference appearances in November–December 2025, publication of preclinical data on LX9851, and upcoming clinical presentations for sotagliflozin. Price reactions have ranged from a gain of 9.86% after a Jefferies conference appearance to a -1.41% move on clinical presentation news, indicating that seemingly routine or positive updates have not produced a consistent directional pattern.

Market Pulse Summary

This announcement highlights Lexicon’s engagement in the chronic pain policy dialogue, emphasizing a...

Analysis

This announcement highlights Lexicon’s engagement in the chronic pain policy dialogue, emphasizing access to safe, effective non-opioid treatments for over 60 million Americans. In the past six months, company news has focused on conferences, preclinical data, and investor outreach, with varied market reactions. Investors may monitor how advocacy around the Relief of Chronic Pain Act, future clinical data, and funding disclosures in recent filings intersect with Lexicon’s strategic positioning in non-opioid therapies.

Key Terms

non-opioid, Medicare

2 terms

non-opioid medical

"focused on accelerating innovation and expanding access to novel non-opioid therapies-"

Non-opioid describes medicines or therapies that relieve pain or treat conditions without using opioid drugs, which act on the brain’s opioid receptors. For investors, non-opioid products matter because they often face fewer addiction and regulatory risks, may win faster approvals or wider adoption, and can open new markets much like a different tool in a toolbox that solves the same problem without the same safety concerns.

Medicare regulatory

"would ensure Medicare coverage for non-opioid medications specifically indicated"

Medicare is a large government-run health insurance program that primarily covers people aged 65 and older and certain younger people with disabilities. For investors it matters because Medicare acts like a huge customer and rule-maker for hospitals, drugmakers and medical-device companies—its coverage decisions, payment rates and regulatory policies can change demand, revenue and profit margins across the healthcare sector, similar to how a major client or regulator can shape a business’s prospects.

AI-generated analysis. Not financial advice.

-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies-

-Need for swift action by policymakers to support millions of Americans suffering from chronic pain-

THE WOODLANDS, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- In October 2025, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) convened an in-person Roundtable in Washington, D.C., to better understand the unmet needs of people living with chronic pain and identify what more can be done to benefit patients and society at large. The White Paper summarizing the findings, titled “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain,” is available as a free download here.

Chronic pain affects one in four American adults and is one of the leading causes of disability, driving direct medical spending, disability claims, and lost productivity each year. Chronic pain costs the United States more than $720 billion annually, including an estimated $190 billion in lost worker productivity¹. More than 20 million people suffer from high-impact chronic pain that disrupts daily activities and makes working difficult or impossible. For many years, opioids have been the default treatment option for severe pain, leaving patients and clinicians to navigate the tradeoff between meaningful relief and significant risks of drug diversion, addiction, and overdose.

The Relief of Chronic Pain Act, recently introduced in the U.S. Senate, would ensure Medicare coverage for non-opioid medications specifically indicated for certain chronic pain conditions. It would also reduce or eliminate several barriers that often block timely access to needed care.

“We are exploring with partners how to add chronic pain to the legislative agenda, and how to help policymakers and payers prioritize new methods of pain relief,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “We believe that non-opioid treatments are going to be incredibly important, not only for the patient, but for society at large.”

Achieving meaningful progress will require a coalition of patients, caregivers, clinicians, patient advocacy groups, professional societies, and others. Swift action to expand access to safe, effective, non-opioid treatments for the more than 60 million Americans living with chronic pain is necessary to achieve progress.

Chronic pain does not discriminate based on demographics and political viewpoints. It affects rural, suburban, and urban communities alike. It impacts every generation. Addressing it must be a bipartisan, nationwide effort—one that reflects the best of what America can accomplish.

Click here to download “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com.

References
¹Guy GP Jr, et al. Economic costs of chronic pain—United States, 2021. Med Care. 2025 Sep. Available from: https://pubmed.ncbi.nlm.nih.gov/40730349/

For Investor and Media Inquiries
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

FAQ

What did Lexicon Pharmaceuticals announce on January 9, 2026 about chronic pain (LXRX)?

Lexicon published a white paper from an October 2025 Roundtable titled “Relief is Possible” focused on access to non-opioid chronic pain treatments.

How many Americans does the Lexicon white paper say live with chronic pain?

The paper states chronic pain affects one in four American adults and more than 60 million people overall.

What economic figures does the Lexicon white paper cite about chronic pain?

It cites an annual U.S. cost of more than $720 billion, including an estimated $190 billion in lost worker productivity.

What policy action does Lexicon reference that could affect access to non-opioid treatments (LXRX)?

The paper references the Relief of Chronic Pain Act, recently introduced in the U.S. Senate, which would ensure Medicare coverage and reduce barriers for certain non-opioid medications.

Where can investors and stakeholders access the Lexicon white paper mentioned by LXRX?

The white paper is available as a free download from Lexicon's published release on January 9, 2026.